Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

9.00
-0.3300-3.54%
Post-market: 9.350.3500+3.89%18:59 EDT
Volume:34.31K
Turnover:313.13K
Market Cap:86.28M
PE:14.06
High:9.53
Open:9.23
Low:8.94
Close:9.33
52wk High:29.98
52wk Low:6.53
Shares:9.59M
Float Shares:7.29M
Volume Ratio:0.64
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6400
EPS(LYR):0.0175
ROE:19.64%
ROA:-42.25%
PB:1.95
PE(LYR):514.20

Loading ...

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire
·
Nov 05, 2025

Huawei's Chinese EV partner Seres' shares slide in Hong Kong debut amid tech slump

Reuters
·
Nov 05, 2025

Seres Therapeutics Inc expected to post earnings of $1.28 a share - Earnings Preview

Reuters
·
Nov 03, 2025

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

GlobeNewswire
·
Oct 30, 2025

Seres Therapeutics Secures $3.6 Million CARB-X Grant to Develop Liquid SER-155 for Infection Prevention

Reuters
·
Oct 29, 2025

Seres Therapeutics Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial

Reuters
·
Oct 14, 2025

Seres Therapeutics Cuts Costs to Extend Cash Runway

TIPRANKS
·
Oct 04, 2025

ADVISORY-Dated alerts on Seres Therapeutics' measures to cut costs withdrawn

Reuters
·
Oct 04, 2025

Seres Therapeutics Inc - Announces Actions to Reduce Operating Costs - SEC Filing

THOMSON REUTERS
·
Oct 04, 2025

Seres Therapeutics Inc - Reducing Workforce by About 25% - SEC Filing

THOMSON REUTERS
·
Oct 04, 2025

Seres Therapeutics Cuts Workforce by 25% to Extend Cash Runway Into Q2 2026

Reuters
·
Oct 04, 2025

FACTBOX-More companies adopt co-CEO structure

Reuters
·
Sep 30, 2025

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Sep 24, 2025

Seres Therapeutics price target raised to $22 from $14 at Canaccord

TIPRANKS
·
Sep 24, 2025

U.S. RESEARCH ROUNDUP-Autozone, Pfizer, Valley National Bancorp

Reuters
·
Sep 24, 2025

Seres Therapeutics Inc : Canaccord Genuity Raises Target Price to $22 From $14

THOMSON REUTERS
·
Sep 24, 2025

Seres Therapeutics to Cut Staff by 25%, Extend Cash Runway

Dow Jones
·
Sep 23, 2025

Seres Therapeutics announces further constructive feedback from FDA on SER-155

TIPRANKS
·
Sep 23, 2025

BRIEF-Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Reuters
·
Sep 23, 2025

Seres Therapeutics Inc - Reduces Workforce by 25% to Extend Cash Runway

THOMSON REUTERS
·
Sep 23, 2025